Follow the Prothena Corp plc share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €425.1m. The latest transaction was disclosed on 15 January 2016 (Levée d'options). Among the most active insiders: Walker Karin L. All data is free.
10
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Prothena Corp plc Buy (bullish), based on 5 analysts. Average price target: US$21.40.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
600 sharesOrdinary Shares, par value $0.01 per shareSEC:0000899243-16-011134:3
10 of 10 declarations
About Prothena Corp plc
Prothena Corp plc is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative diseases. It is listed on NASDAQ under the ticker PRTA.